SARS-CoV-2 infection and lung cancer : potential therapeutic modalities

Gupta, I ORCID: https://orcid.org/0000-0002-8627-3186, Rizeq, B ORCID: https://orcid.org/0000-0001-5859-3804, Elkord, E ORCID: https://orcid.org/0000-0002-3868-0318, Vranic, S ORCID: https://orcid.org/0000-0001-9743-7265 and Al Moustafa, A-E ORCID: https://orcid.org/0000-0003-4452-3439 2020, 'SARS-CoV-2 infection and lung cancer : potential therapeutic modalities' , Cancers, 12 (8) , e2186.

Preview

PDF - Published Version Available under License Creative Commons Attribution 4.0. Download (1MB) | Preview

Abstract

Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer.

Item Type:	Article
Additional Information:	** From MDPI via Jisc Publications Router ** Licence for this article: https://creativecommons.org/licenses/by/4.0/ **Journal IDs: eissn 2072-6694 **History: published 05-08-2020; accepted 15-07-2020
Schools:	Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title:	Cancers
Publisher:	MDPI
ISSN:	2072-6694
Related URLs:	Publication
Funders:	Qatar University
SWORD Depositor:	Publications Router
Depositing User:	Publications Router
Date Deposited:	11 Aug 2020 13:01
Last Modified:	16 Feb 2022 05:19
URI:	https://usir.salford.ac.uk/id/eprint/57910

Actions (login required)

Edit record (repository staff only)